Zentalis Pharmaceuticals (ZNTL) Share-based Compensation (2019 - 2026)

Zentalis Pharmaceuticals' Share-based Compensation history runs 8 years deep, the most recent figure standing at $3.2 million for Q1 2026.

• On a quarterly basis, Share-based Compensation fell 50.71% year-over-year to $3.2 million in Q1 2026; TTM through Mar 2026 was -$3.3 million, a 48.18% increase from a year earlier, with the FY2023 full-year figure at $54.8 million, changed N/A from the prior year.
• Share-based Compensation advanced to $3.2 million in Q1 2026 per ZNTL's latest filing, from -$17.6 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $16.8 million in Q2 2022 and bottomed at -$37.2 million in Q4 2022.
• The 5-year median for Share-based Compensation is $10.3 million (2022), against an average of $3.4 million.
• Across the five-year window, Share-based Compensation soared 137.28% in 2023 and plunged 358.69% in 2024, its largest moves.
• Year by year, Share-based Compensation stood at -$37.2 million in 2022, then surged by 137.28% to $13.9 million in 2023, then tumbled by 358.69% to -$35.9 million in 2024, then jumped by 50.98% to -$17.6 million in 2025, then surged by 118.16% to $3.2 million in 2026.
• Per Business Quant, the three latest ZNTL Share-based Compensation figures stand at $3.2 million (Q1 2026), -$17.6 million (Q4 2025), and $4.8 million (Q3 2025).